Fisher Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Fisher Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$10.1M	Buy	+105,999	New	+$11.3M	﹤0.01%	414

Other funds holding RYTM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Fisher Asset Management's RYTM Position: Q3 2026 in Review

Fisher Asset Management opened a new position in Rhythm Pharmaceuticals (RYTM) in Q3 2026: 105,999 shares worth $10.1M. The stake represents ﹤0.01% of the portfolio and ranks #414 among its holdings.

148 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.

Fisher Asset Management held 105,999 shares of Rhythm Pharmaceuticals worth $10.1M as of Q3 2026.
Rhythm Pharmaceuticals was a new Fisher Asset Management position in Q3 2026.
Rhythm Pharmaceuticals made up ﹤0.01% of Fisher Asset Management's portfolio in Q3 2026, its #414 holding.
148 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.

Based on Fisher Asset Management's 13F filing for Q3 2026, filed 6 Nov 2026.